PFIZER Inc said it will apply to U.S. health regulators on Friday for emergency use authorization (EUA) of its COVID-19 vaccine, the first such application in a major step toward providing protection against the new coronavirus.
The application to the U.S. Food and Drug Administration (FDA) comes just days after Pfizer and German partner BioNTech SE reported final trial results that showed the vaccine was 95% effective in preventing COVID-19 with no major safety concerns.
Pfizer's shares rose 2% and BioNTech climbed 5% on the news that a vaccine could soon be available, raising hopes for the end of a pandemic that has claimed more than a quarter of a million lives in the United States and over 1.3 million worldwide.
The application also includes safety data on about 100 children 12-15 years of age. The company said 45% of U.S. trial participants are 56-85 years old.
"Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine," Pfizer Chief Executive Officer Albert Bourla said in a statement.
The companies expect the FDA to grant the EUA by mid-December and said they will begin shipping doses almost immediately. Pfizer has said it expects to have 50 million vaccine doses ready this year, enough to protect 25 million people.
An FDA advisory committee tentatively plans to meet Dec. 8-10 to discuss the vaccine, a source familiar with the situation told Reuters, though the dates could change.
The final trial data showed the vaccine provided a similar level of protection across different ages and ethnicities - an encouraging result as the disease disproportionately hurts the elderly and minorities.
Of the 170 volunteers who contracted COVID-19 in Pfizer's trial involving over 43,000 people, 162 had received only a placebo, meaning the vaccine was 95% effective, far higher than originally expected. U.S. FDA had set minimum bar for efficacy of 50%.
Pfizer said nearly 42% of global participants and 30% of U.S. participants in the Phase 3 study have racially and ethnically diverse backgrounds.
Moderna Inc is expected to be the next company to seek a U.S. emergency use nod for a COVID-19 vaccine. An initial analysis of data from its late-stage trial showed the vaccine was 94.5% effective. Final results and safety data are expected in the coming days or weeks.
Both the Pfizer/BioNTech and Moderna vaccines work using a new technology to trigger an immune response known as synthetic messenger RNA that can be produced at scale much more quickly than traditional vaccines.
Of dozens of drugmakers and research institutions racing to develop COVID-19 vaccines, the next late-stage data is expected to come from AstraZeneca Plc, which is working with the University of Oxford, in November or December.
Johnson & Johnson said it expects to have data needed to seek U.S. authorization for its experimental vaccine by February.
Reuters
Fri Nov 20 2020
Syringes are seen in front of displayed Biontech and Pfizer logos in this illustration taken November 10, 2020. - Filepic/REUTERS
Mahkamah Persekutuan ganti hukuman mati pendandan rambut lelaki dengan penjara 40 tahun
Dalam penghakimannya, Tengku Maimun berkata hukuman mati Teh diketepikan dan diganti dengan hukuman penjara yang bermula dari tarikh dia ditangkap iaitu pada 15 Sept 2008.
Kerajaan negeri cadang skim khas untuk kakitangan awam kesihatan Johor Selatan
Kerajaan Johor mencadangkan kewujudan skim khas atau insentif khas kepada kakitangan awam kesihatan yang bertugas di Johor Selatan bagi mengisi kekosongan penjawatan sektor berkenaan.
Tumpuan Jumaat – 16 Mei 2024
Ikuti rangkuman berita utama yang menjadi tumpuan di Astro AWANI.
Seorang lelaki selamat, seorang lagi hilang dalam tragedi memancing di Tasik Pedu
Mangsa dipercayai melakukan aktiviti memancing bersama rakannya sebelum terjatuh ke dalam tasik.
Tiket Kejohanan Badminton Masters Malaysia 2024 laris
Bahang kehangatan penganjuran Kejohanan Badminton Masters Malaysia 2024 di Axiata Arena Bukit Jalil dari 21 hingga 26 Mei ini kian dirasai selepas tiket kejohanan itu laris terjual.
Pengurus syarikat rugi lebih RM400,000 terpedaya pelaburan tidak wujud
Seorang pengurus syarikat swasta kerugian RM401,075 akibat menjadi mangsa sindiket penipuan pelaburan tidak wujud secara dalam talian.
Pasaran getah Malaysia ditutup tinggi, seiring niaga hadapan getah serantau
Pada 5 petang, harga rujukan getah fizikal LGM bagi GMM 20 berada pada 781 sen sekilogram manakala susu getah pukal pada 729.5 sen sekilogram.
Hoki Dalam Dewan Piala Asia: Malaysia raih tempat ketiga
Kemenangan tersebut mengulangi pencapaian dilakar pada edisi 2010, 2012 dan 2022.
PM Singapura Wong bercakap dengan PM Anwar, pemimpin lain pada hari pertama bertugas
Perdana Menteri Singapura Lawrence Wong hari ini bercakap dengan pemimpin di rantau ini melalui telefon pada hari pertama beliau memegang jawatan, termasuk dengan Anwar.
PM ucap Hari Guru, rakam jutaan penghargaan buat warga pendidik
Perdana Menteri Datuk Seri Anwar Ibrahim hari ini mengucapkan Selamat Hari Guru kepada seluruh warga pendidik yang gigih membina bangsa.
COVID-19: Vaksin mungkin peroleh lesen dalam beberapa minggu - Kementerian Kesihatan India
Pegawai kesihatan berkata syarikat pengeluar vaksin Serum Institute of India sudah memohon kelulusan bagi penggunaan kecemasan di India.
COVID-19: KKM masih menunggu dokumen Pfizer berhubung status vaksin
KKM masih belum terima sebarang dokumen daripada Pfizer berhubung status terkini vaksin COVID-19
Pfizer dan BioNtech kemuka permohonan kelulusan kecemasan penggunaan vaksin di AS, Eropah
Permohonan rasmi yang dikemukakan kedua-dua syarikat itu kepada Agensi Perubatan Eropah (EMA) dibuat sehari selepas permohonan sama dikemukaan di AS dan Britain.
COVID-19: Australia pula umum vaksin selamat dan berkesan
Vaksin itu membuktikan ia selamat melalui ujian klinikal fasa satu dan terbukti menghasilkan tindak balas antibodi positif.